The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
The much criticised takeover of Idera by Biocryst will not, after all, take place.